or Try an Advanced Search...

    Technical Analysis for IMVT - Immunovant, Inc.

    Grade Last Price % Change Price Change
    D 28.05 -2.94% -0.85
    IMVT closed down 2.94 percent on Thursday, November 14, 2024, on 1.26 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical IMVT trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish 0.00%
    NR7 Range Contraction 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -2.94%
    200 DMA Resistance Bearish -2.94%
    50 DMA Resistance Bearish -2.94%
    Older End-of-Day Signals for IMVT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 7 hours ago
    Down 2 % about 8 hours ago
    Fell Below Previous Day's Low about 8 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    Fell Below Lower Bollinger Band about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    IMVT Chart by TradingView
    Basic chart:

    Profile

    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Immune System Autoimmune Disease Eye Antibodies Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis Warm Autoimmune Hemolytic Anemia

    Is IMVT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Q2 2024 Roivant Sciences Ltd Earnings Call
    Nov 8 Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
    Nov 7 Immunovant GAAP EPS of -$0.74
    Nov 7 Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
    Oct 29 Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
    Oct 14 Immunovant: Switching Lead Candidates Increases Risk
    Oct 1 Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?
    Sep 30 Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?
    Sep 9 Immunovant stock falls 8% amid Graves' disease program update
    Sep 9 What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
    See more IMVT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 45.58
    52 Week Low 24.67
    Average Volume 860,626
    200-Day Moving Average 30.18
    50-Day Moving Average 29.60
    20-Day Moving Average 29.85
    10-Day Moving Average 29.85
    Average True Range 1.32
    RSI (14) 40.12
    ADX 11.47
    +DI 16.11
    -DI 25.65
    Chandelier Exit (Long, 3 ATRs) 28.13
    Chandelier Exit (Short, 3 ATRs) 31.98
    Upper Bollinger Bands 31.35
    Lower Bollinger Band 28.34
    Percent B (%b) -0.1
    BandWidth 10.10
    MACD Line -0.08
    MACD Signal Line 0.10
    MACD Histogram -0.1818
    Fundamentals Value
    Market Cap 4.06 Billion
    Num Shares 145 Million
    EPS -1.96
    Price-to-Earnings (P/E) Ratio -14.31
    Price-to-Sales 0.00
    Price-to-Book 20.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 29.52
    Resistance 3 (R3) 29.67 29.33 29.28
    Resistance 2 (R2) 29.33 28.96 29.26 29.19
    Resistance 1 (R1) 28.69 28.72 28.52 28.54 29.11
    Pivot Point 28.35 28.35 28.27 28.28 28.35
    Support 1 (S1) 27.71 27.98 27.54 27.56 26.99
    Support 2 (S2) 27.37 27.74 27.30 26.91
    Support 3 (S3) 26.73 27.37 26.83
    Support 4 (S4) 26.58